Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer

NCT01940172 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed Epithelial Ovarian Cancer
Relapsed Primary Peritoneal Cancer
Relapsed Fallopian Tube Cancer

Interventions

DRUG: Birinapant
DRUG: Conatumumab

Sponsor

TetraLogic Pharmaceuticals